Drug intelligence / Profile preview

Etsyl

Development stage: Preclinical
Lead developer: 3D Bio-Tissues
Modality: Peptides
Administration: Topical

Overview

Etsyl is a proprietary lipopeptide developed by 3D Bio-Tissues (3DBT), a UK-based biotech company and subsidiary of BSF Enterprise PLC. The active ingredient is a lipopeptide designed to stimulate cellular collagen production in human skin cells. Etsyl is being developed for dual applications in the cosmetics and pharmacological sectors. In cosmetics, it is intended as a bioactive ingredient for anti-aging and moisturizing formulations. In pharmacology, it has potential applications in wound healing and the development of skin substitutes. As of 2023, 3D Bio-Tissues has entered into a proof-of-concept agreement with a major cosmetic company to evaluate Etsyl for use in topical skin cream solutions.

Brand names: Etsyl

Beyond the preview

Go deeper on Etsyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Etsyl.

Explore the full profile